Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: A systematic review

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 4, 2007, Pages 724-732

  Nicastri, Emanuele ^a   Leone, Sebastiano ^a   Angeletti, Claudio ^a   Palmisano, Lucia ^b   Sarmati, Loredana ^c   Chiesi, Antonio ^b   Geraci, Andrea ^b   Vella, Stefano ^b   Narciso, Pasquale ^a   Corpolongo, Angela ^a   Andreoni, Massimo ^c  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Gender; HAART; Long term clinical progression

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; RITONAVIR;

CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFORMATION RETRIEVAL; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MALE; MEDLINE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PUBLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW; VIRUS IMMUNITY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; SEX FACTORS; TREATMENT OUTCOME;

EID: 34548818164     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm302     Document Type: Review

References (52)

1. Moore J, Schuman P, Schoenbaum E et al. Severe adverse Life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS 1999; 13 2459-68.
2. Bozzette SA, Barry SH, Duan, N et al. The care of HIV-infected adults in the United States. N Engl J Med 1998; 339: 1897-904.
3. Sterling TR, Vlahov D, Astemborski J et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344: 720-5.
4. Fardet L, Mary-Krause M, Heard I et al. Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response. HIV Med 2006; 7: 520-9.
5. Murri R, Lepri AC, Phillips et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: Evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr 2003; 34: 184-90.
6. Sayles JN, Wong MD, Cunningham WE. The inability to take medications openly at home: Does it help explain gender disparities in HAART use? J Womens Health 2006; 15: 173-81.
7. Gebo KA, Fleishman JA, Conviser R et al. HIV Research Network. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005; 38: 96-103.
8. Giordano TP, White AC Jr, Sajja P et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003; 32: 399-405.
9. McNaghten AD, Hanson DL, Dworkin MS et al. Adult/Adolescent Spectrum of HIV Disease Group. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2003; 32: 499-505.
10. Hunt PW, Deeks SG, Rodriguez B et al. Continued CD4 cell count' increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 1907-15.
11. Nicastri E, Angeletti C, Palmisano L et al. Gander differences in clinical progression. of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005; 19: 577-83.
12. Moore AL, Kirk O, Johnson AM et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: The gender issue revisited. J Acquir Immune Defic Syndr 2003; 32: 452-61.
13. Kuyper LM, Wood E, Montaner JS et al. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J Acquir Immune Defic Syndr 2004; 37: 1470-6.
14. O'Connell JM, Braitstein P, Hogg RS et al. Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme. Antivir Ther 2003; 8: 569-76.
15. Abgrall S, Yeni PG, Bouchaud O et al. Clinical Epidemiology Group from the French Hospital Database on HIV. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. AIDS 2006; 20: 2099-106.
16. Hoen B, Fournier I, Lacabaratz C et al. Structured treatment interruptions in primary HIV-1 infection: The ANRS; 100 PRIMSTOP trial. J Acquir Immune Defic Syndr 2005; 40: 307-16.
17. Bedimo h, Chen RY, Westfall AO et al. Sustained HIV viral suppression following treatment interruption: An observational study. AIDS Res Hum Retroviruses 2006; 22: 40-4.
18. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20: 1391-9.
19. Wang C, Masho S, Nixon D et al. When to start HAART for the treatment of HIV infection. Lancet Infect Dis 2007; 7: 5-6.
20. Ammassari A, Antinori A, Cozzi-Lepri A et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002; 31: S140-4.
21. Turner BJ, Laine C, Cosler L et al. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users.J Gen Intern Med 2003; 18: 248-57.
22. Palepu A, Tyndall MW, Chan K et al. Initiating highly active antiretroviral therapy and continuity of HIV care: The impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther 2004; 9: 713-9.
23. Touloumi G, Pantazis N, Antoniou A et al. CASCADE Collaboration. Highly active antiretroviral therapy interruption: Predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr 2006; 42: 554-61.
24. Hulgan T, Shepherd BE, Raffanti SP et al. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2007; 195: 425-31.
25. Egger M, May M, Cherie GF et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
26. Moore AL, Sabin CA, Johnson MA et al. Gender and clinical outcomes after starting highly active antiretroviral treatment: A cohort study. J Acquir Immune Defic Syndr 2002; 29: 197-202.
27. Hall HI, McDavid K, Ling Q et al. Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann Epidemiol 2006; 16: 824-33.
28. Ferradini L, Jeannin A, Pinoges L et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment. Lancet 2006; 22; 367: 1335-42.
29. Calmy A Pinoges L, Szumilin E. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: Multicentric observational cohort. AIDS 2006; 20: 1163-9
30. Perez-Hoyos S, del Amo J, Muga R et al. Effectiveness of highly active antiretroviral theraphy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003; 17: 353-9.
31. de la Hera MG, Ferreros I, del Amo J et al. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. J. Epidemiol Community Health 2004, 58: 944-50.
32. Porter K, Babiker A, Bhaskaran K et al. CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction HAART. Lancet 2003; 362: 1267-74.
33. Antinori A, Larussa D, Cingolani A et al. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis 2004; 39: 1681-91.
34. Betz ME, Gebo KA, Barber E et al. Patterns of diagnoses in hospital admissions in a multistate cohort of HIV-positive adults in 2001. Med Care 2005; 43: 13-4.
35. Floris-Moore M, Lo Y, Klein RS et al. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34: 331-7.
36. Palepu A, Sun H, Kuyper L et al. Predictors of early hospital readmission in HIV-infected patients with pneumonia. J Gen Intern Med 2003; 18: 242-7.
37. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: Long term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-16.
38. Richter A, Pladevall M, Manjunath et al. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: A retrospective cohort study. HIV Med 2005; 6: 79-90.
39. Galli M, Cozzi-Lepri A, Ridolfo AL et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: The LipolCoNa Study. Arch Intern Med 2002; 162: 2621-8.
40. Bonfanti P, Gulisano C, Ricci E et al. Risk factors for lipodystrophy in the CISAI cohort. Biomed Pharmacother 2003; 57 422-7.
41. Heath KV, Chan KJ, Singer J et al. Incidence of morphological and lipid abnormalities: Gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol 2002; 31: 1016-20.
42. Santos CP, Felipe YX, Braga PE et al. Self-perception of body changes in persons living with HIV/AIDS: Prevalence and associated factors. AIDS 2005; 4: 14-21.
43. Geddes R, Knight S, Moosa MY et al. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006; 96: 722-4.
44. Boulassel MR, Morales R, Murphy T et al. Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons. J Med Virol 2006; 78: 1158-63.
45. Floridia M, Bucciardini R, Fragola V et al. Risk factors and occurrence of rash in HIV-positlve patients not receiving nonnucleoside reverse transcriptase inhibitor: Data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL). HIV Med 2004; 5: 1-10.
46. van Leth F, Andrews S, Grinsztejn B et al. The effect of baseline CD4 call count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19 463-71.
47. Umeh OC, Curder JS. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol 2006; 2 273-83.
48. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update. Infect Genet Evol 2007; 7: 333-42.
49. Collazos J, Asensi V, Carton JA; for the Grupo Espanol para el Estudio Multifactorial de la Adherencia (GEEMA). Sex differences in the clinical, immunological and virological parameters of HIV-Infected patients treated with HAART. AIDS 2097; 21: 835-43.
50. Mills EJ, Nachega JB, Buchan I et al. Adherence to antiretroviral therapy in sub-Saharan Africa and N America: A meta-analysis. JAMA 2006; 296: 679-90.
51. Saw PS, Otieno LF, Bissagnen E et al. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: Clinical results from 4 African countries. J Acquir Immune Defic Syndr 2007; 44: 262-7.
52. Currier J, Spino C, Cotton DJ. The impact of accrual rates of women on the ability to detect gerder differences in toxicity rates and response to therapy in clinical trials. In: Abstracts of VIII International Conference on AIDS, Amsterdam, Netherlands, 1992. Abstract C-329, p. 4705.